<DOC>
	<DOCNO>NCT00985556</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin , S-1 , capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . It yet know whether give oxaliplatin together S-1 effective give oxaliplatin together capecitabine . PURPOSE : This randomized phase II trial study well give oxaliplatin together S-1 work compare oxaliplatin give together capecitabine treat patient recurrent , metastatic , unresectable gastric cancer .</brief_summary>
	<brief_title>Oxaliplatin S-1 Oxaliplatin Capecitabine Treating Patients With Recurrent , Metastatic , Unresectable Gastric Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate time progression patient recurrent metastatic gastric cancer treat oxaliplatin combination S-1 v capecitabine . Secondary - To assess progression-free survival , overall response , disease-control rate , time-to-treatment failure , response duration , time response , overall survival , safety , quality life , pharmacogenetics , psychologic distress/coping strategy . OUTLINE : This multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral S-1 twice daily day 1-14 oxaliplatin IV 2 hour day 1 . - Arm II : Patients receive oral capecitabine twice daily day 1-14 oxaliplatin arm I . Courses arm repeat every 3 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 2 month 6 month .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma stomach Unresectable advance disease recurrent disease resection At least one radiographically document ( CT scan MRI ) measurable evaluable lesion previously nonirradiated area accord RECIST No clinical evidence brain metastasis history CNS disease unless adequately treat PATIENT CHARACTERISTICS : ECOG performance status 02 Estimated life expectancy &gt; 3 month Hemoglobin ≥ 9 g/dL White blood cell ≥ 4,000/µL ANC ≥ 2,000/µL Platelets ≥ 100,000/µL Bilirubin ≤ 1.25 time upper limit normal ( ULN ) ( ≤ 2.0 time ULN hepatic metastasis present ) Serum creatinine ≤ 1.5 time ULN Creatinine clearance ≥ 60 mL/min AST/ALT ≤ 3.0 time ULN ( ≤ 5.0 time ULN hepatic metastasis present ) Alkaline phosphatase ≤ 3.0 time ULN ( ≤ 5.0 time ULN bone metastasis present ) Must intact gastrointestinal tract Able take oral medication No medically uncontrolled severe infection complication No prior malignancy gastric cancer last 5 year except basal cell cancer skin preinvasive cancer cervix Not pregnant nursing No neuropathy ≥ grade 2 No clinically relevant heart disease No evidence past medical history psychosocial dysfunction contraindicates use investigational drug put patient risk No dementia , alter mental status , psychiatric condition would prohibit understanding rendering inform consent No uncontrolled hepatitis B C , chronic liver disease , diabetes mellitus No evidence inappropriate suspicious condition PRIOR CONCURRENT THERAPY : No prior chemotherapy advance recurrent disease Prior adjuvant chemotherapy allow finish &gt; 6 month start study treatment No prior therapeutic radiotherapy Prior palliative radiotherapy allow do primary , evaluable , intraabdominal lesion No prior capecitabine oxaliplatin No concurrent chemotherapy radiotherapy ( except localize radiotherapy pain relief ) No concurrent chemically related analogue , warfarin , phenytoin , allopurinol No concurrent steroid therapy except follow : Prophylactic use hypersensitivity control antiemetic purpose allow Chronic low dose steroid ( less methylprednisolone 20 mg equivalent dose ) allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>stage IIIA gastric cancer</keyword>
	<keyword>stage IIIB gastric cancer</keyword>
	<keyword>stage IIIC gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
</DOC>